IDG Capital — 2021 Investments
5 investments dated 2021 · listed companies and verified rows first · show all
Accutar Biotech applies artificial intelligence to drug discovery, using a hybrid approach of computational drug design followed by wet lab validation to reduce the time and cost of developing new drugs.
AI & Machine LearningBiotechDeep TechNew York, US
Jie Fan(Founder)inWei He(Executive Officer)Yimin Qian(Executive Officer)Xiangyan Sun(Executive Officer)Quan Zhou(Director)Long Zhu(Director)
Co-investors5Y CapitalCoatue ManagementYF CapitalZhenFund
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
Co-investorsLAVLilly Asia VenturesWI Harper Group3H Health InvestmentAlwin CapitalBioTrack Capital+2 more
Beijing-based beverage maker, formerly Genki Forest, selling sugar-free sparkling water and flavored teas in China and abroad.
Binsen Tang(Founder)Tang Binsen(Founder)
Co-investorsK3 VenturesK3V VenturesWarburg PincusCoatue ManagementGaorong VenturesGenesis Capital+5 more
BIT Invest, a flagship unit of BIT Group, offers investment solutions for cryptocurrency and digital asset holders, including structured products, fixed income instruments, and lending services secured by digital collateral.
Crypto & Web3Fintech
John Ge(Founder)inJihan Wu(Founder)in
Co-investorsBlockchain CoinvestorsFenbushi CapitalHash GlobalK3 VenturesParadigmQiming Venture Partners+10 more
Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases.
BiotechDeep TechHealthtech
Liqun Wang(Founder)
Co-investorsPan-Lin CapitalAlwin CapitalLilly Asia VenturesSherpa Healthcare Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.













